Sutro Biopharma (STRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $154.72M
Last updated: Nov 17, 2026 at 4:15 PM ET
Sutro Biopharma (STRO) Statistics
Sutro Biopharma (STRO) has a market cap of $154.72M and an enterprise value of $107.87M. Its share count is up 94.17% from a year earlier. It kept -344.22% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 30.28% below the market cap, as cash exceeds debt.
| Market Cap | $154.72M |
|---|---|
| Enterprise Value | $107.87M |
| Latest price (Nov 17, 2026) | $8.92 |
Key Dates
The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 3.3x. Its year-end P/S ranged from 1.0x to 6.0x from 2019 to 2025.
| P/S Ratio | 3.3x |
|---|---|
| Forward P/S | 3.2x |
Price Statistics
The stock is down 1.41% over 52 weeks and trades 30.09% below its 50-day average.
| Beta (1Y) | 1.54 |
|---|---|
| 52-Week Change | -1.41% |
| 1-Month Change | -20.75% |
| 3-Month Change | -59.29% |
| 6-Month Change | -71.83% |
| 5-Year Change | -95.49% |
| Total Return (1Y) | -1.41% |
| Total Return (3Y CAGR) | -30.78% |
| Total Return (5Y CAGR) | -45.25% |
| Return vs SPY (1Y) | -11.33% |
| Max Drawdown (1Y) | -78.32% |
| Max Drawdown (3Y) | -90.72% |
| Sharpe Ratio (1Y) | 0.00 |
| Correlation with SPY (1Y) | 0.25 |
| 50-Day Average | $12.76 |
| 200-Day Average | $22.70 |
| 52-Week Range | $7.15 to $43.85 |
| RSI (14 Days) | 35.0 |
| Average Volume (20 Days) | 326.12K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.94x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 2.94x |
|---|---|
| Quick Ratio | 2.94x |
| Debt / Equity | 0.00x |
| Interest Coverage | -2.84x |
Returns and Efficiency
| Return on Assets (ROA) | -87.90% |
|---|---|
| Return on Capital Employed (ROCE) | -97.72% |
| ROA (5Y Average) | -50.31% |
| Asset Turnover | 0.23x |
| Receivables Turnover | 4.85x |
Scores
STRO has an Altman Z-Score of -9.59, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -9.59 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $45.11M over the last 12 months is down 57.30% from the 12 months before.
| Revenue | $45.11M |
|---|---|
| Revenue Growth (YoY) | -57.30% |
| Gross Profit | $45.11M |
| Operating Income | -$119.55M |
| Pretax Income | -$155.36M |
| Net Income | -$155.27M |
| EBITDA | -$115.87M |
| EBIT | -$119.55M |
| Reported EPS (TTM) | -$12.62 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $46.85M |
|---|---|
| Total Debt | $0 |
| Net Cash | $46.85M |
| Net Cash Per Share | $2.83 |
| Working Capital | $105.19M |
| Shareholder Equity | -$132.54M |
| Total Assets | $176.65M |
| Total Liabilities | $309.18M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$129.44M |
|---|---|
| FCF Per Share | -$7.83 |
| Depreciation and Amortization | $7.14M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -265.03%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -265.03% |
| Pretax Margin | -344.42% |
| Net Margin | -344.22% |
| EBITDA Margin | -256.88% |
| EBIT Margin | -265.03% |
Growth
Revenue grew 14.78% a year over 3 years.
| Revenue Growth (3Y CAGR) | +14.78% |
|---|---|
| Revenue Growth (5Y CAGR) | +19.12% |
Dividends and Yields
STRO does not pay a dividend.
| Buyback Yield | -69.55% |
|---|---|
| Shareholder Yield | -69.55% |
Stock Splits
The last split was a 1-for-10 reverse split on Dec 3, 2025.
| Last Split Date | Dec 3, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 4 similar companies, STRO has the lowest P/S.
P/S RatioPeer median 110.5x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -19.75%
| P/S Ratio | 3.3x vs 110.5x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -57.30% vs -19.75% median |
Analyst Forecast
Consensus estimates put revenue growth at -43.77% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -43.77% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About STRO
What is STRO's market cap?
Sutro Biopharma has a market cap of $154.72M. Its enterprise value, which adds debt and subtracts cash, is $107.87M.
How many shares of STRO are outstanding?
Sutro Biopharma has 16.58M shares outstanding. The count is up 94.17% from a year earlier.
Does STRO pay a dividend?
No. Sutro Biopharma does not pay a dividend.
How much debt does STRO have?
Sutro Biopharma has $0 of total debt and $46.85M of cash and equivalents, a net cash position of $46.85M.
STRO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors